UKHSA study shows RSV vaccine highly effective in preventing hospitalisation: United Kingdom Saturday, August 2, 2025, 10:00 Hrs [IST] A new UK Health Security Agency study - Effe ...

Increases in COVID, RSV, and influenza are the result of governments refusal to enact public health measures and address ...

All three can be given in one visit, usually at no cost under federal rules and private-insurance coverage. If you’re unsure ...

Moderna Inc. (NASDAQ:MRNA) reported on Friday a second-quarter loss of $2.13 per share, beating the consensus of a $2.98 loss ...

The Ministry of Public Health’s latest epidemiological bulletin paints a stark picture of rising respiratory infections and a ...

The layoffs are part of an ongoing effort to reduce operating costs amid government and competitive challenges to its vaccine ...

Moderna Inc. shares declined as the company’s cost-cutting efforts failed to assuage investors who are worried about the ...

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13)Updates 2025 projected revenue range to $1.5 to $2.2 billion, reflecting a $300 million ...

Pediatricians are urged to follow 2024 guidelines amid ACIP upheaval, vaccine hesitancy, and access issues as children head ...

Pregnant individuals commonly reported hesitancy toward RSVpreF and nirsevimab, indicating the need for efforts to promote the safety and uptake of RSV immunization.